Prana Therapies
Prana Therapies is a clinical-stage biotechnology company developing next-generation, half-life-extended multispecific antibodies for inflammatory diseases. Its proprietary INSPIRE platform combines complementary therapeutic mechanisms into single IgG-based molecules, enabling enhanced efficacy and infrequent at-home dosing. The lead candidate, PRA-216, a bispecific antibody targeting IL-4Rα and TSLP, is in Phase 2 development for asthma, COPD, and atopic dermatitis.
- Drug Discovery & Therapeutics
- Biotechnology
- Healthcare Technology
Funding
Founders
Founder details are not available yet.
Product
Problem
Conventional multispecific antibody formats often face significant limitations including poor half-life, stability challenges, manufacturability issues, immunogenicity risks, and difficulties with subcutaneous delivery. These constraints hinder the development of therapies that combine multiple complementary mechanisms into a single drug while maintaining the drug-like properties needed for convenient, patient-friendly dosing.
Solution
Prana Therapies provides a proprietary INSPIRE platform that engineers fully IgG-based multispecific antibodies designed to overcome the key limitations of conventional formats. The platform combines complementary therapeutic mechanisms within a single molecule, enabling enhanced efficacy, extended half-life, low immunogenicity, and high-concentration subcutaneous delivery for infrequent, at-home dosing. The lead program, PRA-216, is a fully human, half-life-extended bispecific antibody targeting IL-4Rα and TSLP, combining broad downstream blockade of IL-4 and IL-13 signaling with upstream TSLP inhibition. Phase 1 data demonstrated rapid, deep, and durable pharmacodynamic activity across multiple Type 2 inflammatory biomarkers, with extended exposure supporting maintenance dosing every eight to 12 weeks. The platform is modular and scalable, allowing generation of differentiated candidates across targets and therapeutic areas.
Target Audience
Primary customers are patients with respiratory and dermatologic inflammatory diseases including asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and eosinophilic esophagitis, as well as the healthcare providers and clinical researchers treating these conditions.
Features
- Fully IgG-based multispecific format engineered for enhanced stability, manufacturability, and drug-like properties
- Half-life extension technology supporting infrequent, at-home subcutaneous dosing every 8-12 weeks
- Combination of complementary mechanisms (e.g., IL-4Rα blockade with TSLP inhibition in PRA-216) to address multiple inflammatory drivers
- Low immunogenicity profile designed for chronic disease treatment
- Modular and scalable platform enabling rapid generation of candidates across targets and therapeutic areas
- Pipeline includes a second program: an IL-31 containing bispecific antibody for atopic dermatitis, with first-in-human studies expected in the second half of 2027